- Home
- CMBT vs NAMS Comparison
CMBT vs NAMS Comparison
Compare CMBT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBT
- NAMS
- Stock Information
- Founded
- CMBT 1989
- NAMS 2019
- Country
- CMBT Belgium
- NAMS Netherlands
- Employees
- CMBT N/A
- NAMS N/A
- Industry
- CMBT
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- CMBT
- NAMS Health Care
- Exchange
- CMBT NYSE
- NAMS Nasdaq
- Market Cap
- CMBT 1.9B
- NAMS 2.2B
- IPO Year
- CMBT N/A
- NAMS N/A
- Fundamental
- Price
- CMBT $8.83
- NAMS $18.11
- Analyst Decision
- CMBT
- NAMS Strong Buy
- Analyst Count
- CMBT 0
- NAMS 6
- Target Price
- CMBT N/A
- NAMS $42.83
- AVG Volume (30 Days)
- CMBT 136.6K
- NAMS 694.5K
- Earning Date
- CMBT 05-21-2025
- NAMS 05-08-2025
- Dividend Yield
- CMBT 13.02%
- NAMS N/A
- EPS Growth
- CMBT N/A
- NAMS N/A
- EPS
- CMBT 2.16
- NAMS N/A
- Revenue
- CMBT $934,913,000.00
- NAMS $47,140,000.00
- Revenue This Year
- CMBT $5.05
- NAMS N/A
- Revenue Next Year
- CMBT $24.22
- NAMS N/A
- P/E Ratio
- CMBT $4.18
- NAMS N/A
- Revenue Growth
- CMBT N/A
- NAMS 586.97
- 52 Week Low
- CMBT $7.65
- NAMS $14.06
- 52 Week High
- CMBT $18.43
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- CMBT 44.37
- NAMS 47.80
- Support Level
- CMBT $8.65
- NAMS $16.79
- Resistance Level
- CMBT $9.61
- NAMS $19.58
- Average True Range (ATR)
- CMBT 0.35
- NAMS 0.94
- MACD
- CMBT -0.05
- NAMS -0.12
- Stochastic Oscillator
- CMBT 17.14
- NAMS 47.07
About CMBT EURONAV
CMB.Tech NV owns and operates a fleet of vessels for international maritime shipping and storage of crude oil and petroleum products. It generate a large parts of their revenue from voyage charters, including vessels in pools that predominantly perform voyage charters. The company organizes itself into three divisons: the Marine division, the H2 Infra division and the H2 Industry division. The Marine Division derives maximum revenue.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.